These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment. Ribeiro PD, Ribeiro OD, Marcolan AM, Medina-Acosta E. Peptides; 2003 Nov; 24(11):1829-36. PubMed ID: 15019216 [Abstract] [Full Text] [Related]
5. Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, Silvestri C, Licci A, Łukasiak J, Saba V, Scalise G. J Infect Dis; 2005 Nov 01; 192(9):1613-20. PubMed ID: 16206076 [Abstract] [Full Text] [Related]
7. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. Dell'Acqua G, Giacometti A, Cirioni O, Ghiselli R, Saba V, Scalise G, Gov Y, Balaban N. J Infect Dis; 2004 Jul 15; 190(2):318-20. PubMed ID: 15216467 [Abstract] [Full Text] [Related]
8. RIP-V improves murine survival in a sepsis model by down-regulating RNAIII expression and α-hemolysin release of methicillin-resistant Staphylococcus aureus. Ma B, Zhou Y, Li M, Yu Q, Xue X, Li Z, Da F, Hou Z, Luo X. Pharmazie; 2015 Feb 15; 70(2):81-7. PubMed ID: 25997246 [Abstract] [Full Text] [Related]
10. RNAIII-inhibiting-peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation. Anguita-Alonso P, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Saba V, Scalise G, Sevo M, Tuzova M, Patel R, Balaban N. Antimicrob Agents Chemother; 2007 Jul 15; 51(7):2594-6. PubMed ID: 17116671 [Abstract] [Full Text] [Related]
11. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Callegan MC, Hobden JA, Hill JM, Insler MS, O'Callaghan RJ. Invest Ophthalmol Vis Sci; 1992 Oct 15; 33(11):3017-23. PubMed ID: 1399405 [Abstract] [Full Text] [Related]
12. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model. Atahan E, Gul M, Ergun Y, Eroglu E. Eur J Vasc Endovasc Surg; 2007 Aug 15; 34(2):182-7. PubMed ID: 17481929 [Abstract] [Full Text] [Related]
13. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM. J Antimicrob Chemother; 2009 Apr 15; 63(4):763-6. PubMed ID: 19155225 [Abstract] [Full Text] [Related]
14. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, Viticchi C, Del Prete MS, Saba V, Scalise G, Dell'Acqua G. J Infect Dis; 2003 Feb 15; 187(4):625-30. PubMed ID: 12599079 [Abstract] [Full Text] [Related]